- Global Pharma News & Resources

Quanta Announces Formation of North American Medical Advisory Board

Esteemed Group of Kidney Care Thought Leaders to Provide Clinical Insights and Expertise

BEVERLY, Mass.--(BUSINESS WIRE)--Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB). This group of highly esteemed kidney care thought leaders will provide clinical expertise and guidance as Quanta brings its portable hemodialysis system SC+ to the United States market to enable greater flexibility in the delivery of life sustaining dialysis care.

The Medical Advisory Board consists of prominent nephrologists and is chaired by Dr. Paul Komenda, chief medical officer (CMO) at Quanta. Bringing to bear extensive clinical and academic research, Dr. Komenda is a fellow of both the American Society of Nephrology and the Royal College of Physicians and Surgeons, Canada. Additionally, Dr. Komenda has authored and published over 160 peer-reviewed articles focusing on health services research, home dialysis and clinical nephrology.

“I am thrilled to welcome this diverse group of nephrologists who are performing at the top of their field to our North American Medical Advisory Board,” said Dr. Komenda. “The Medical Advisory Board’s experience and insights will be critical as we explore how to best leverage the proven benefits of SC+ to serve patients and providers in the United States dialysis market.”

Members of Quanta’s North American Medical Advisory Board include:

  • Dr. Christos Argyropoulos, MD: Dr. Christos Argyropoulos is the division chief of nephrology at the University of New Mexico Health Sciences Center. He currently conducts research on kidney related biomarkers, middle molecule removal by dialysis platforms and big data. Dr. Argyropoulos' clinical interests focus on outreach nephrology, home dialysis and diabetic kidney disease. Dr. Argyropoulos trained in internal medicine at the University of Cincinnati and in nephrology and transplant nephrology at the University of Pittsburgh Medical Center.
  • Dr. Christopher Chan, MD, FRCPC: Dr. Chan is the divisional director of nephrology, professor of medicine, and holds the R Fraser Elliott Chair in Home Dialysis at the Toronto General Hospital, University Health Network in Canada. He is also the deputy physician in chief of economics at the University Health Network. He serves as associate editor for the Clinical Journal of the American Society of Nephrology. Dr. Chan joined the division of nephrology at Toronto General Hospital, University Health Network in 2002, after completing post-graduate training in internal medicine and nephrology at the University of Toronto. He has contributed over 200 peer-reviewed articles and has written extensively on home dialysis.
  • Dr. Shaminder Gupta, MD: Dr. Gupta has been a practicing nephrologist in Louisiana for 17 years where he focuses on the long-term management of chronic kidney disease and end-stage renal disease. He has a special interest in population health and has served as the state lead for hypertension and chronic kidney disease in Louisiana. He is currently the corporate medical director of Monogram Health, a kidney disease benefit management and care delivery company, and chief medical officer of Monogram Kidney Care Clinic, an in-home and virtual kidney clinic that provides leading care in 20 states. He previously served as president of the National Kidney Foundation of Louisiana and founded its home dialysis task force.
  • Dr. Andrew E. Lazar, MD: Dr. Lazar is the chief of nephrology at Ahuja Medical Center in Cleveland, Ohio. In addition, he is a consulting medical director for Natera where he works to promote the use of genetic testing for kidney disease patients. He is also medical director at both Dialyze Direct and Renew Dialysis. He is the founder of Peloton Medical Devices, a medical engineering company focused on the development of a dialysis safety device. He also founded Cleveland Kidney Disease Associates and Affiliated Dialysis of Ohio, which is now owned and operated by Dialyze Direct. Affiliated Dialysis of Ohio was the first provider of home dialysis therapies in nursing home facilities for the state of Ohio. Dr. Lazar also started Cleveland Home Dialysis, one of the largest providers of home hemodialysis and peritoneal dialysis in Northeast Ohio.
  • Dr. Bijal V. Patel, MD: Dr. Patel is the director of home therapies for Balboa Nephrology Medical Group (BNMG), chief of nephrology for Sharp Rees-Stealy and physician home champion for Fresenius Kidney Care. He previously served as medical advisor for Cricket Health. Through the practice of medicine, Dr. Patel strives to give patients the best opportunity to live well with kidney disease. By overcoming barriers, educating patients, and addressing social determinants of health, he achieves high rates of home modalities and living donor transplantation. Dr. Patel currently serves as chairman of the board for BNMG and has been named San Diego’s top doctor in the field of nephrology by San Diego Magazine for the last eight years in a row.
  • Dr. Brigitte Schiller, MD: Dr. Schiller is CMO at Satellite Healthcare where she has been responsible for quality, physician leadership, and research and development since 2010. As CMO, Dr. Schiller leads efforts to improve and transform the delivery of care to more than 8,000 dialysis patients with more than 20% of these patients undergoing home dialysis. She also serves as chief of staff for the Medical Director Nephrologists and directs Satellite Healthcare’s applied pragmatic clinical research efforts. Dr. Schiller has participated as investigator in multiple United States Food & Drug Administration (FDA) trials and is a published author in many areas of end-stage renal disease care, including home dialysis. She serves on the expert panel for the United States Renal Data System database.

“This is a pivotal moment for Quanta, as we start to bring SC+ to the United States to help improve how patients receive dialysis care,” said John E. Milad, CEO of Quanta. “We are privileged to work with such a distinguished group of nephrologists as members of our Medical Advisory Board. This ensures that we will have the guidance and insights needed to make a positive impact on dialysis experiences for both patients and healthcare providers.”

The launch of Quanta’s North American Medical Advisory Board comes on the heels of the Company’s $245 million Series D funding round announced earlier this summer. This funding will accelerate Quanta’s global operational development and United States commercial roll-out, strongly positioning to company to pursue a $12 billion total addressable market opportunity in the United States alone.

About Hemodialysis

Hemodialysis is a life sustaining treatment for patients with kidney failure to help normalize blood chemistry and remove waste products and excess fluids.

About Quanta and SC+

Quanta is enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely. Headquartered in the United Kingdom and with operations in the United States, Quanta is a trans-Atlantic commercial-stage medical technology innovator.

Quanta’s lead product, SC+, is a portable, simple and powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the United States, SC+ is FDA cleared for use in acute and chronic care facilities, and in the United Kingdom it is CE marked, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home.

The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted through a small, lightweight, disposable cartridge. The simple-to-use and digitally connected design of SC+ is intended to empower dialysis users to take greater control of dialysis care. Meanwhile, as a portable and powerful device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Learn more at


For more information about Quanta:
Kavita Bouknight

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Sep-2021